Thompson is a lot more invested in the nuts-and-bolts of GMO modifications than shareholders
Darryl, I hope you are right. However, Thompson has been struggling to develop GMO silks for a long time. They started with Piggabac, then perhaps migrated to zinc fingers, before moving on to Crispr/cas. KBLB has paid for a number of different GMO strains to be developed, most of which have apparently been abandoned. So the thought that KBLB could design an effective GMO organism without all the expensive trial-and-error probably seems like a big breakthrough to Thompson.
I agree that investors really want to hear about production, sales, partnerships, and such. If I'm right, we will have to wait a little longer for sales and partnerships information than March 19. Nothing in the PR announcing the webcast suggests we will be hearing about those developments.
Won't have to wait much longer for the news. Best to all longs.
Market Data 
Markets 
AI
